New Pharmacy Prior Authorization Programs
Wellmark Blue Cross and Blue Shield is implementing three new pharmacy prior authorization programs to encourage generic drug use and
support the most clinically effective drug therapy at the lowest net spend.
Sedative Hypnotics Prior Authorization
Sedative hypnotics are sleep aid drugs such as Ambien, Ambien CR, Sonata, Lunesta, and Rozerem. To encourage use of generic Ambien, Wellmark is implementing a new prior authorization process for sedative hypnotics effective September 15, 2007.
Under the new program, a member must try and fail generic Ambien (zolpidem tartrate) before coverage is available for Ambien CR, Sonata, Lunesta, and Rozerem. This program goes into effect for all members currently taking a sedative hypnotic, as well as new users.
If the physician would like the member to continue on their current sedative hypnotic drug rather than move to generic Ambien and there is no claims history in the system for Ambien or its generic equivalent, the physician will need to request approval from Wellmark. Approval will be granted if the physician can document that the member has tried and failed Ambien in the past.
Generic Ambien is a Tier 1 drug on the Wellmark Drug List, while the other sedative hypnotics are on Tier 3. In May, Wellmark sent a postcard to all members taking a sedative hypnotic to inform them about the availability of generic Ambien and how this new option may help decrease their out-of-pocket costs.
| Drug Name |
Dosage |
Number of Tablets |
Price |
Generic Ambien
(zolpidem tartrate) |
5 mg
10 mg |
30
30 |
$15.39
$19.39 |
| Ambien |
5 mg
10 mg |
30
30 |
$134.12
$134.12 |
| Ambien CR |
6.25 mg
12.5 mg |
30
30 |
$109.17
$109.17 |
| Sonata |
5 mg
10 mg |
30
30 |
$106.91
$103.63 |
| Lunesta |
1 mg
2 mg
3 mg |
30
30
30 |
$125.34
$127.52
$127.52 |
| Rozerem |
8 mg |
30 |
$95.46 |
| Prices from www.drugstore.com, July 19, 2007 |
Non-Sedating Antihistamine Prior Authorization
The FDA recently approved a new drug called Xyzal, a non-sedating antihistamine. Xyzal is
similar to both Allegra (which is also available as a generic) and Zyrtec (which is expected to be available without a prescription in 2008, similar to Claritin).
To encourage the use of established non-sedating antihistamines, Wellmark has implemented a prior authorization for Xyzal. Members will be required to try and fail generic Allegra and Zyrtec before coverage is available for Xyzal.
Because the prior authorization was in place before Xyzal was available to purchase (although the drug has been approved by the FDA, it was not being sold at the time this newsletter was published), this prior authorization does not impact current users of non-sedating antihistamines.
Antifungal Prior Authorization Change
Antifungals are drugs such as Penlac, Sporanox, and Lamisil that are frequently used to treat nail fungus (onychomychosis), which is generally considered a cosmetic condition. These drugs
currently require a prior authorization. Effective September 15, 2007, Wellmark is changing its prior authorization criteria to no longer provide coverage for Penlac, Sporanox, Lamisil, and their generic equivalents when prescribed for cosmetic purposes.
If the antifungal is being prescribed for medical rather than cosmetic purposes, the physician will need to submit a prior authorization request to Wellmark for approval.
Wellmark currently has similar prior authorization policies in place for drugs such as Retin-A. Coverage for Retin-A is not available if it is being prescribed for treatment of wrinkles, which is considered a cosmetic condition. But Retin-A is covered for a diagnosis such as skin cancer, for example, if prior authorization approval is received. |